DPP抑制剂西格列汀在型糖尿病患者综合管理中的优势-培训课件.pptVIP

* 44 Talking Points Here is an illustration of the effect of JANUMET. The combination of sitagliptin and metformin improves blood glucose control via complementary mechanisms. Sitagliptin increases insulin synthesis and release from the beta cells and indirectly reduces glucose overproduction in the liver through suppression of glucagon from the alpha cells. Metformin increases insulin sensitivity by decreasing the release of free fatty acids from fat to muscle and liver and by increasing insulin receptor activity in muscle. By increasing insulin sensitivity, metformin increases glucose uptake and utilization in muscle and fat. Metformin also decreases glucose overproduction by directly targeting the liver to decrease gluconeogenesis and glycogenolysis. In combination, these agents help to improve glycemic control as a result of their complementary mechanisms. Sitagliptin addresses beta-cell dysfunction, metformin addresses insulin resistance, and both sitagliptin and metformin address glucose overproduction but in different, complementary ways. References: MMF4 – slide 32 (graphics and notes) Purpose: To show how metformin and sitagliptin act differently but in a complementary manner. Takeaway: JANUMET addresses the core defects of type 2 diabetes. * Initial Combination Therapy With Sitagliptin Plus Metformin Provided Greater HbA1c Reductions Through 104 Weeks=26个月 This slide demonstrates that after initial therapy with sitagliptin plus metformin, the HbA1c change from baseline to 104 weeks was generally greater than that achieved with either agent alone.1 This all-patients-treateda analysis (extension study) included patients with a baseline measurement and at least 1 measurement in the extension study.1 aResults include only randomized patients who agreed to enter the extension study, had not received glycemic rescue therapy through week 54, took at least 1 dose of study medication after week 54, and had at least 1 post-54-week HbA1c measurement. Re